Expertise in
22
conditions

Dr. David E. Bernstein

Gastroenterology
King Kullen Pharmacies Corp
185 Central Ave, 
Bethpage, NY 
34 Years of Experience
Expertise in
22
conditions
King Kullen Pharmacies Corp
185 Central Ave, 
Bethpage, NY 

Overview

David Bernstein is a Gastroenterologist practicing medicine in Bethpage, New York. He has been practicing medicine for over 34 years.

Dr. Bernstein is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Non-Alcoholic Fatty Liver Disease, Gastrectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 23 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

Nyu Langone Hospitals

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

King Kullen Pharmacies Corp
185 Central Ave, Bethpage, NY 11714

Additional Areas of Focus

Dr. Bernstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: HTD1801 (BUDCA)
Study Phase: Phase 2
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
Enrollment Status: Completed
Publish Date: July 14, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: February 18, 2026
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)
Enrollment Status: Terminated
Publish Date: March 18, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy & Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

28 Total Publications

Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis.
Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis.
Journal: Hepatology communications
Published: May 18, 2021
Similar Doctors
Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Referral may be required

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (26.9 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist practicing medicine in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Referral may be required

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (24.8 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Schiano is a Gastroenterologist practicing medicine in New York, New York. Dr. Schiano is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Kidney Transplant. Dr. Schiano is currently accepting new patients.

Expertise in
22
conditions
Dr. Ira M. Jacobson
Gastroenterology
Expertise in
22
conditions
Dr. Ira M. Jacobson
Gastroenterology
Referral may be required

New York University

530 1st Ave, 
New York, NY 
 (26.2 miles away)
212-263-0474
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Gastroenterologist practicing medicine in New York, New York. He has been practicing medicine for over 47 years. Dr. Jacobson is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Non-Alcoholic Fatty Liver Disease, Liver Transplant, and Endoscopy.

Frequently Asked Questions about Dr. David E. Bernstein

How do I make an appointment with Dr. David E. Bernstein?

You can book an appointment with Dr. David E. Bernstein by calling their office at 516-758-8600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David E. Bernstein a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David E. Bernstein is classified as an Elite expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David E. Bernstein specialize in?

While Dr. David E. Bernstein is a Gastroenterology, they have specific expertise in Hepatitis, Hepatitis C, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. David E. Bernstein participate in research or clinical trials?

Yes. Dr. David E. Bernstein has published 28 articles and abstracts on conditions like Hepatitis. You can view a list of Dr. David E. Bernstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David E. Bernstein accept my insurance?

Dr. David E. Bernstein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 516-758-8600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile